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• Insulin is the key hormone regulating glucose homeo- 
stasis and has many cellular effects on metabolism, growth, 
and differentiation. Its action is mediated through a specific 
cell surface receptor. The first step following insulin binding 
consists of receptor autophosphorylation and stimulation of 
its tyrosine kinase activity. Among the multiple substrates the 
insulin receptor substrate-1 is the major cytoplasmic substrate. 
It binds several Src homology 2 proteins through its multiple 
tyrosine phosphorylation sites: phosphatidylinositol 3-kinase, 
the ras guanine nucle-otide-releasing complex growth factor 
receptor-boundprotein-2/son of sevenlessprotein, the tyrosine 
phosphatase Syp, and the adapter protein Nek. Insulin recep- 
tor substrate-1 is essential for many, but not all of the insulin 
biological responses. Recently, a primary alternative substrate, 
insulin receptor substrate-2, was purified and cloned. Numer- 
ous biochemical abnormalities of the insulin signaling sys- 
tem lead to insulin resistance. The recent data about the mo- 
lecular mechanisms of insulin action may provide new insights 
into the pathophysiology and therapy of diabetes mellitus and 
other insulin resistance states. 
INTRODUCTION 
• Insulin has been the model polypeptide hormone in 
many ways, being the first purified, crystallized, and synthe- 
sized by chemical and molecular biology techniques. Insulin 
is the key hormone regulating glucose homeostasis. Its major 
target tissues are liver, skeletal muscle and adipose tissue. At 
cellular level, insulin activates glucose and amino acids trans- 
port, lipid and glycogen metabolism, protein synthesis, and 
transcription of specific genes. Its action is mediated by spe- 
cific plasma membrane receptor. Insulin receptor binding ini- 
tiates a multitude of effects on metabolism, growth, and dif- 
ferentiation. The insulin receptor is a transmembrane glyco- 
protein with intrinsic protein tyrosine kinase activity, like the 
receptors for epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), insulin-like growth factor-I (IGF-I) etc. 
It is present in virtually all vertebrate tissues, although the 
concentration varies from 40 receptors in erythrocytes to more 
than 200 000 receptors in adipocytes and hepatocytes. The 
insulin receptor is tetrameric, consisting of two 120 kD oc- 
and two 90 kD p-subunits. The two a-subunits are disulphide- 
linked, entirely extracellular, and contain insulin-binding sites. 
The unoccupied a-subunit inhibits the tyrosine kinase activ- 
ity of p-subunit. Each p-subunit is disulphide-linked to an ce- 
subunit, spans the plasma membrane, and contains a tyrosine 
kinase domain in its intracellular portion. The first step fol- 
lowing insulin binding consists of receptor autophosphorylation 
on multiple specific sites and phosphorylation of cellular sub- 
strates. The p-subunit contains several functional regions, in- 
cluding ATP-binding and autophosphorylation sites in the 
intracellular domain and a regulatory region at the COOH 
(C-) terminus. The association of insulin with the receptor 
stimulates its tyrosine kinase activity. The C-terminus may 
play a regulatory role but is not essential for signaling (1-4). 
Recent data suggest that the acidic region including residues 
1270-1280 of the insulin receptor C-terminus is involved in 
(/') receptor binding with histone, an exogenous substrate of 
the receptor kinase, and (/'/) regulation of receptor autophos- 
phorylation and kinase activity. Thus this insulin receptor 
  
  
domain could interact with cellular proteins modulating the 
receptor kinase (5). The intracellular domain of the (3-subumt 
is essential for signal transduction (4). 
For a long time it was believed that the effects of insulin are 
mediated by a unique insulin receptor. However, there is con- 
siderable evidence suggesting that insulin receptors in brain, 
liver, adipocytes, and lymphocytes are heterogeneous in struc- 
ture and function. This evidence is based on comparisons of 
concentration-response curves in cells and tissues, and on com- 
parisons of binding and effects of insulin-derivatives and re- 
ceptor antibodies. Two insulin receptor isoforms (IR-A and 
IR-B) generated by alternative mRNA splicing were identi- 
fied but could not fully account for the observed differences in 
ligand binding and receptor function. It was suggested that 
the differences in ligand binding reflected posttranslational 
modifications, and that postreceptor events were responsible 
for the heterogeneity of insulin action (6). 
The insulin receptor also mediates internalization of insulin. 
At least two pathways for endocytosis exist at varying degrees 
in all cells. The coated pit/vesicle-mediated pathway requires 
a functional insulin receptor, triphosphorylation in the regu- 
latory region and intact intracellular domain. Some cells con- 
tain a constitutive pathway which does not require receptor 
autophosphorylation or an intact intracellular region. Insulin 
action may be mediated by receptor internalization and inter- 
action with its substrate(s) associated with endomembranes. 
A small fraction of phosphorylated insulin receptors is suffi- 
cient for signal transduction (7). pp!20/HA4 is a hepatocyte 
membrane glycoprotein phosphorylated by the insulin recep- 
tor tyrosine kinase, which is part of a protein complex required 
for receptor-mediated internalization of insulin. It is possible 
that this function is regulated by insulin-induced phosphory- 
lation of the intracellular domain of pp!20/HA4 (8). 
INSULIN RECEPTOR SUBSTRATE-1 
• Insulin receptor substrate-1 (IRS-1) is the major cyto- 
plasmic substrate of insulin and IGF-I receptors. This was ini- 
tially detected in insulin-stimulated Fao hepatoma cells by 
immunoprecipitation with high affinity antiphosphotyrosine 
antibodies and was originally called pp!85 based on migra- 
tion during SDS-PAGE. IRS-1 was purified and cloned from 
several sources. The amino acid sequences of rat, mouse and 
human IRS-1 defined from the cDNA derived from rat liver, 
mouse adipocytes, human muscle, and human hepatocellular 
carcinoma are now known. IRS-1 contains 21 potential ty- 
rosine phosphorylation sites and about 40 potential serine/ 
threonine phosphorylation sites in motifs recognized by vari- 
ous kinases, including 12 ones for casein kinase II, 5 for pro- 
tein kinase A (PKA), and 16 for PKC. IRS-1 binds several Src 
homology 2 (SH2) proteins through its multiple tyrosine phos- 
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phorylation sites. Each SH2 domain, which consists of ap- 
proximately 100 amino acids, constitutes a binding site for 
Tyr(P) within a specific peptide context. Tyr(P)-IRS-l was 
found to associate with four SH2 domain proteins through their 
SH2 domains: phosphatidylinositol 3-kinase (PI,-kinase), the 
ras guanine-nucleotide-releasing complex GRB-2-SOS, the ty- 
rosine phosphatase Syp, and the adapter protein Nek (4,9). 
Insulin receptors phosphorylate IRS-1 at the plasma membrane, 
probably in coated pits. A desensitization mechanism is pos- 
sible in which the tyrosine-phosphorylated membrane-bound 
IRS-1 associated with signaling molecules such as PI3-kinase, 
is released into the cytoplasm in concert with its serine/threo- 
nine phosphorylation (10). 
Recently, Sun et al (11) purified and cloned 4PS, the major 
substrate for the interleukin-4 (IL-4) receptor-associated ty- 
rosine kinase in myeloid cells, which had significant struc- 
tural similarity to IRS-1. 
Transgenic mice lacking IRS-1 are resistant to insulin and 
IGF-1, but exhibit significant residual insulin action which 
corresponds to the presence of an alternative high molecular 
weight substrate in liver and muscle. 4PS is the primary alter- 
native substrate, i.e. IRS-2, which plays a major role in physi- 
ologic insulin signal transduction via both Pl.-kinase activa- 
tion and GRB-2/SOS association. In IRS- 1-deficient mice, 4PS/ 
IRS-2 provides signal transduction to these two major path- 
ways of insulin signaling (12).  
In IRS-1 knockout mice, insulin signals are thought to be 
mediated by IRS-2 (pp!90), which is an alternative signaling 
molecule. pp!90 is a 190-kD IRS-1-like protein in simian COS 
cells, which is slightly larger than IRS-1 (pp!80) of human, 
rat, and mouse cells. The deduced amino acid sequence of 
COS pp!90 consists of 1251 amino acids and is 96.4%, 87.9% 
and 88.7% identical to human, mouse and rat IRS-1, respec- 
tively. The COS pp!90 binds to SH2 domains of p85, GRB-2/ 
Ash, and Syp, as do IRS-1. The COS pp!90 may be a simian 
homologue of IRS-1, but not of IRS-2. Chinese hamster ovary 
(CHO) cells have not only the IRS-1 gene but also a gene 
related to the COS pp!90 (13). 
IRS-1 pathway may be involved in omithine decarboxylase 
induction. The absence of a difference in ornithine decarboxy- 
lase and PI3-kinase activity in the regenerating liver between 
IRS-1-deficient mice and wild-type ones may be related to the 
compensatory effects of IRS-2/ppl90 (14). IRS-1 is essential 
for some, if not all, of insulin biological responses. Major in- 
sulin signals such as stimulation of glucose uptake and DNA 
synthesis and modification of hexose metabolism are medi- 
ated by the tyrosine-phosphorylated IRS-1 in many cell spe- 
cies (4,10). However, several studies suggest that some insu- 
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lin effects, including those in the nucleus, may not be regu- 
lated by this pathway. Different mechanisms are involved in 
induction of c-fos and early-growth-regulatory-1 (egr-l) 
mRNA expression by insulin, the former by the more classic 
insulin receptor tyrosine kinase pathway and the latter by a 
not well-defined alternative signal transduction pathway (15). 
IRS-1 tyrosine phosphorylation is sufficient to increase the 
mitogenic response to insulin, whereas insulin stimulation of 
glycogen synthesis appears to involve other factors (16). 
IRS-1 discriminates the signals generated by the insulin re- 
ceptor and other receptor tyrosine kinases by binding and regu- 
lating a specific subset of SH2 domain-containing signaling 
molecules. For example, the receptors for insulin and PDGF 
are tyrosine kinases that mediate distinct effects in identical 
cellular backgrounds. Each receptor engages an unique subset 
of the signaling elements available, at least partly through the 
selection of proteins with SH2 proteins. Autophosphorylation 
sites in the PDGF receptors (PDGFR) directly bind SH2 pro- 
teins, whereas activation of the insulin receptor leads to phos- 
phorylation of IRS-1, which in turn binds SH2 proteins. In 
HIR 3.5 cells, which contain similar numbers of PDGF and 
insulin receptors, insulin, but not PDGF, stimulates tyrosyl 
phosphorylation of IRS-1. Similarly, insulin, but not PDGF, 
treatment of HTR 3.5 stimulates the association of IRS-1 with 
PI,-kinase, although PDGF stimulates the association of PI3- 
kinase with the tyrosine-phosphorylated PDGFR. Association 
with IRS-1 activates PI,,-kinase more effectively than that with 
the PDGFR. Whereas the PDGFR associate with PI3-kinase, 
ras-GAP, GRB-2, and phospholipase Cy, only GRB-2 andPI3- 
kinase associates with IRS-1. Moreover, PDGF, but not insu- 
lin, caused tyrosine phosphorylation of phospholipase Cy in 
HIR 3.5 ceUs. Thus the insulin signal differs from that of PDGF 
by the insertion of a cytosolic, nonreceptor SH2 domain dock- 
ing protein (IRS-1). Furthermore, ERS-1 binds another subset 
of SH2 domain-containing proteins than does the PDGFR and 
regulates at least one common element (PI,-kinase) differently 
than the PDGFR (17). 
In contrast, IRS-1 or DR.S-2 phosphorylation can converge sig- 
nal pathways from the insulin tyrosine kinase receptor and 
others that do not contain an intrinsic tyrosine kinase domain 
(IL-4 and growth hormone [GH] receptors). IL-4 receptor 
activates PI,-kinase via IRS-1 or the IRS-1-related molecule 
4PS. In primary adipocytes, tyrosine phosphorylation of Janus 
tyrosine kinase-2 (JAK-2) and GH receptor seems to be in- 
volved in the signal transduction leading to insulin-like effects 
of GH. Importantly, the signal pathways for GH and insulin 
clearly differ at the receptor level, but seem to converge at or 
before the level of IRS-1 or IRS-2 phosphorylation that occurs 
in response to both hormones (18).  
Other signaling pathways may also be involved in the media- 
tion of the insulin effects. PKC-oc may be involved in the insu- 
lin induced egr-l expression and cell proliferation, but not in 
the insulin suppressed hepatitis B surface antigen (HBsAg) 
gene expression in human hepatoma cells (19). 
•        Phosphatidylinositol 3-kinase  
Many growth factors, including PDGF, insulin and IL-4, stimu- 
late the phosphorylation of phosphoinositides on 3-position of 
D-myo-inosotiol ring by activating PI3-kinase, the product of 
the VPS34 gene. PI,-kinase is the first SH2 protein associated 
with IRS-1. PI,-kinase is composed of two subunits, a 110 kD 
catalytic (pi 10) subunit and an 85kD regulatory (p85ot) one, 
which possesses two SH2 domains. At least two isoforms of 
p85 are known (p85a and p85[3). p85a is higher expressed 
and functionally better characterized. Insulin stimulates PI3- 
kinase in vivo through interaction between the SH2 domains 
of p85 and IRS-1, whereas a region between both SH2 do- 
mains associates with pi 10. Insulin causes the activation of 
PI,-kinase through complexation of tyrosine-phosphorylated 
YMXM motifs on IRS-1 with the SH2 domains of PI,-kinase. 
Binding of PI,-kinase to phosphorylated IRS-1 leads to ten- 
fold stimulation of its activity, accounting for the rapid rise in 
phosphorylated phosphatidylinositols observed in insulin- 
stimulated cells. For examination which tyrosine residue of 
IRS-1 is required for the interactions of IRS-1 with PI,-ki- 
nase, different rat IRS-1 mutants containing mutations in the 
tyrosine residues that interact with the SH2 domains of PI.- 
kinase in vitro were constructed. Mutation of tyrosine 608 af- 
fects the PI,-kinase activity associated with IRS-1, suggesting 
that this tyrosine is likely to be a principal site of interaction 
with the SH2 domains of p85 in response to insulin (20). PI.- 
kinase can be stimulated via IRS-1 pathway and by other 
ligands. GH-induced tyrosine phosphorylation of IRS-1 and 
the subsequent docking of PL-kinase are importantpostreceptor 
events in GH action (21).  
PI3-kinase regulates the trafficking of lysosomal enzymes by 
interfering with a mannose 6-phosphate receptor-dependent 
sorting event in the trans-Golgi network (22). PI,-kinase ac- 
tivity as well as an intact actin cytoskeletal network are re- 
quired for insulin-stimulated glucose transport in L6 myotubes. 
This process occurs through the translocation of glucose trans- 
porters (GLUT1, GLUT3 and GLUT4) from the trans-Golgi 
network store to the plasma membrane. Glucose transport is 
also stimulated by the mitochondrial ATP production uncoupler 
dinitrophenol, wich induces translocation of GLUT1 and 
GLUT4, but not GLUT3. This response is not affected by in- 
hibiting PI3-kinase or disassembling the actin cytoskeletal net- 
work. Insulin, but not dinitrophenol, causes tyrosine phospho- 
rylation of several proteins, including IRS-1 and mitogen-ac- 
tivated protein (MAP) kinase. Similarly, insulin, but not dini- 
trophenol, induces actin reorganization which is inhibited by 
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wortmannin. Thus insulin and dinitrophenol stimulate glu- 
cose transport by different mechanisms (23). 
The activated PDGFR directly binds and activates PL-kinase, 
whereas the IL-4 receptor activates PI3-kinase via IRS-1 or 
the IRS-1-related molecule 4PS. Although PDGF and IL-4 
can activate PI3-kinase in the respective cell lines, they do not 
possess insulin ability to stimulate glucose uptake and GLUT4 
translocation to the plasma membrane. These findings indi- 
cate that activation of PI,-kinase is not sufficient to stimulate 
GLUT4 translocation to the plsasma membrane. Activation 
of a second signaling pathway by insulin, distinct from PI3- 
kinase, is necessary for the stimulation of glucose uptake in 
insulin-sensitive cells (24). 
Studies with inhibitors have indicated that activation of PI3- 
kinase is required for the stimulation of glucose transport in 
adipocytes. Short peptides containing two tyrosine-phospho- 
rylated or thiophosphorylated YMXM motifs potently activate 
PI3-kinase in the cytosol from 3T3-L1 adipocytes. Introduc- 
tion of the phosphatase-resistant thiophosphorylated peptide 
into 3T3-L1 adipocytes through permeabilization with Sta- 
phylococcus aureus a-toxin stimulates PL-kinase as strongly 
as insulin. However, under the same conditions, this peptide 
increases glucose transport into the permeabilized cells only 
20% as well as insulin. Determination of the distribution of 
GLUT4 by confocal immunofluorescence shows that its trans- 
location to plasma membrane can account for the effect of the 
peptide. Thus, one or more insulin-triggered signaling path- 
ways, besides the PL-kinase one, participate in the stimula- 
tion of glucose transport (25). It has been shown that 
pervanadate (H,O2 and vanadate), but not H,O2 or vanadate 
alone, mimics most insulin actions in CHO cells or CHO cells 
that overexpress wild-type or mutant insulin receptor and/or 
IRS-1. Pervanadate-induced tyrosine phosphorylation of the 
insulin receptor enhances insulin receptor tyrosine kinase ac- 
tivity toward IRS-1 in vivo and fifteenfold IRS-1-associated 
PI,-kinase activity. However, pervanadate treatment does not 
induce insulin receptor/IRS-1 association (26).  
•        Growth factor receptor-bound protein-2 
Growth factor receptor-bound protein-2 (GRB-2) is a 25 kD 
cytosolic protein that contains two SH3 domains and one SH2 
domain that binds to Tyr
895
 in IRS-1. GRB-2 is an "adapter 
molecule" that links the 150 kD guanine nucleotide exchange 
factor for p21ras termed mammalian son-of-sevenless (mSOS) 
to tyrosyl phosphoprotein, such as the EOF receptor, IRS-1, and 
BCR-abl. mSOS catalyses the release of GTP from ras. The 
GRB-2-mSOS unit is considered a complex of a regulatory and 
a catalytic subunit similar to the complex of PI 3-kinase. The 
GRB-2 -mSOS complex thus may activate p21 ras by stimulat- 
ing GTP-binding. The dissociation of GRB-2 from SOS pro- 
teins caused by insulin in 3T3-L1 cells mediates p21ras deac- 
tivation and desensitization (27). Thus the binding of GRB-2- 
mSOS to IRS-1 mediates the insulin stimulation of p2 Iras 
which in turn binds directly Raf-1 serine/threonine kinase, the 
first element of the MAP kinase cascade. Raf-1 activates MAP 
kinase kinase which in turn activates MAP kinase. Insulin 
activates NF-kappa B in mammalian cells through a posttrans- 
lational mechanism requiring both insulin receptor tyrosine 
kinase and Raf-1 kinase activities (28). However, alternative 
pathways for insulin regulation of ras may exist, including 
insulin-stimulated tyrosine phosphorylation of She or the di- 
rect binding of p21 ras to the insulin receptor (4). 
Insulin or EGF stimulation induces a rapid increase in p2 Iras 
levels but after several minutes they decline toward basal de- 
spite ongoing hormone stimulation. The deactivation of p2Iras 
correlates closely with phosphorylation of SOS and dissocia- 
tion of SOS from GRB-2. The inhibition of MAP kinase ki- 
nase blocks both events, resulting in prolonged p21 ras activa- 
tion. Thus, a negative feedback loop exists whereby activation 
of the RafTMAP-ERK-kinase (MEK) cascade by p21 ras causes 
SOS phosphorylation and, therefore, SOS/GRB-2 dissociation, 
limiting the duration of p2Iras activation by growth factors. 
A serine/threonine kinase downstream of MAP kinase kinase 
mediates this desensitization feedback pathway (29). 
The stimulation of the MAP kinase pathway by insulin is re- 
quired for stimulation of pp90 and c-fos, but is not required 
for many of the metabolic activities of the hormone in cul- 
tured fat and muscle cells, basal and insulin-stimulated glu- 
cose uptake, lipogenesis, glycogen synthesis, insulin receptor 
autophosphorylation, activation of protein phosphatase-1 and 
Pl.-kinase (30). 
Other data suggest that signaling molecules other than IRS-1, 
including She, are critical for insulin stimulation of p2Iras. 
IRS-1 phosphorylation is either not sufficient or not involved 
in insulin stimulation (16). 
A SH2 domain-containing protein was identified by yeast two- 
hybrid screen, performing with the cytoplasnuc domain of the 
human insulin receptor as bait to trap high-affinity interact- 
ing proteins encoded by human liver or HeLa cDNA libraries. 
It binds with high affinity to the autophosphorylated insulin 
receptor in vitro. The mRNA for this protein was found by 
Northern blot analysis to be highest in skeletal muscle and 
was also detected in adipocytes by polymerase chain reaction. 
To study the role of this protein in insulin signaling, a full- 
length cDNA encoding this protein (called GRB-IR) was iso- 
lated and stably expressed in CHO cells overexpressing the 
human insulin receptor. Insulin treatment of these cells leads 
to in situ formation of a complex of the insulin receptor and 
the 60 kD GRB-IR. Although almost 75% of the GRB-IR pro- 
  
Mitev and Sirakov 50 
Blamed Rev 5,1996 
Insulin signaling and resistance 
  
tein is bound to the insulin receptor, it is only weakly tyrosine- 
phosphorylated. The formation of this complex appears to in- 
hibit the insulin-induced increase in tyrosine phosphorylation 
of two endogenous substrates, a 60 kD GTPase-activating pro- 
tein and, to a lesser extent, IRS-1. The subsequent association 
of this latter protein with PI3-kinase is also inhibited. GRB-IR 
is probably a SH2-domain-containing protein that directly com- 
plexes with the IR and serves to inhibit signaling or redirect 
the insulin receptor signaling pathway (31). 
•        Protein tyrosine phosphatase Syp 
Syp is an ubiquitously expressed protein tyrosine phosphatase 
(FTP) that contains two amino-terminal SH2 domains respon- 
sible for its association with tyrosine-phosphorylated proteins. 





 totally prevents the 
insulin-induced association of IRS-1 with the SH2 domains of 
PTP2C, demonstrating that both tyrosines are key elements in 
the binding sites for the SH2 domains of PTP2C. The ability 
of purified PTP2C to dephosphorylate IRS-1 depends on the 
association of PTP2C with phosphorylated IRS-1 (20). The 
association of Syp with phosphopeptides containing a consen- 
sus binding motif, YVNI, activates the phosphatase, suggest- 
ing a role for IRS-1 in the activation of this signal pathway. 
One role of this assotiation is likely to be the termination of 
signaling from Tyr(P)IRS-l, since Syp rapidly dephosphory- 
lates purified recombinant Tyr(P)-IRS-l. It is also possible 
that Syp has a positive role in signaling, since there is ge- 
netic evidence that the homologous phosphatase in Drosophila, 
the corkscrew gene product, augments signal transduction in 
a pathway involving a receptor tyrosine kinase, ras and Raf 
(9). Expression of dominant interfering mutants of Syp inhib- 
its insulin stimulation of c-fos reporter gene expression and 
activation of the 42 kD (ERK2) and 44 kD (ERK1) MAP ki- 
nases. Cotransfection of dominant interfering SHPTP2 mu- 
tants with v-ras or GRB-2 indicates that SHPTP2 regulates 
insulin signaling either upstream of or in parallel to ras func- 
tion. Furthermore, phosphotyrosine blotting and immunopre- 
cipitation identifies the 125 kD focal adhesion kinase 
(pp!25
FAK
) as a substrate for insulin-dependent tyrosine de- 
phosphorylation. Thus SHPTP2 functions as a positive regu- 
lator of insulin action and that insulin signaling results in the 
dephosphorylation of tyrosine-phosphorylated pp!25
FAK
 (32). 
FTP play a key role in the regulation of insulin action. Insulin 
mediates inhibition of nuclear protein phosphatase-2A (PP- 
2A) which is associated with an increase in phosphorylation 
of the transcription factor cAMP response element-binding 
protein. Insulin inhibits nuclear PP-2A activity, and C-termi- 
nal domain of insulin receptor is important for this effect (33). 
There is relative abundance and subcellular distribution of spe- 
cific PTP in muscle tissue, the major site of insulin-mediated 
glucose disposal in vivo involved in the regulation of revers- 
ible tyrosine phosphorylation in this tissue (34). 
•        Protein Nek 
Nek is a 47 kD protein containing three SH3 domains in addi- 
tion to the SH2 domain. It associates through its SH2 domain 
with Tyr(P)-IRS 1 in CHO cells overexpressing the insulin recep- 
tor. Since the 85 kD subunit of PI3-kinase contains two proline- 
rich motifs that can associate with the v-Src SH3 domain, con- 
sideration should also be given to the possibility that these pro- 
line-rich segments interact with the Nek SH3 domains within a 
tertiary complex of IRS-1, PI3-kinase and Nek (9). 
 
INSULIN RESISTANCE 
• All forms of diabetes mellitus in man are associated 
with some degree of peripheral insulin resistance. In type I 
diabetes, it is unclear whether the insensitivity to the actions 
of insulin on glucose transport is a direct result of low circu- 
lating insulin or a response to hyperglycemia. Non-insulin- 
dependent diabetes mellitus (NTDDM) is a complex metabolic 
disorder that involves numerous biochemical abnormalities, a 
heterogenous clinical picture, and a polygenic hereditary com- 
ponent. The primary causal event in NIDDM is a decrease in 
the maximal stimulation of in vivo glucose disposal. The 
pathophysiologic state involves increased basal hepatic glu- 
cose production, decreased insulin-mediated glucose utiliza- 
tion in target tissues, and altered pancreatic function with de- 
creased p-cell function and enhanced glucagon secretion. Pro- 
spective studies indicate that insulin resistance and hyper- 
insulinemia exist in the prediabetic state at time when glucose 
tolerance is normal. When hyperglycemia supervenes both 
insulin secretion and insulin-mediated glucose utilization are 
further compromised, and mediated in part by sustained 
hyperglycemia itself. Insulin resistance may occur at any level 
in the biological action of insulin, from initial binding to cell 
surface receptors to the phosphorylation cascade initiated by 
autophosphorylation of the insulin receptor. Receptors isolated 
from patients with NIDDM have defective autophosphorylation 
kinase activity when isolated from adipocytes, liver, erythro- 
cytes, and skeletal muscle. The magnitude of the decrease in 
insulin receptor kinase activity correlates with the degree of 
fasting hyperglycemia. However, the defect in insulin recep- 
tor kinase activity normalizes after weight reduction or other 
measures that reduce hyperglycemia indicating the secondary 
nature of the defect. Clarification of the mechanisms underly- 
ing insulin resistance in NIDDM may lead to new treatment 
modalities for this disease (35). Insulin resistance is a com- 
mon clinical feature of obesity and NIDDM, and is character- 
ized by elevated serum levels of glucose, insulin, and lipids. 
The mechanism of acquisition of insulin resistance is unknown 
(2).   
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Insulin resistance of skeletal muscle, liver and fat combined 
with an abnormality of insulin secretion characterizes NIDDM. 
There is increasing evidence that the insulin resistance of the 
skeletal muscle plays a key role early in the development of 
NIDDM. Recent research efforts focuss on the characterization 
of insulin signal transduction elements in the muscle which are 
candidates for a localization of a defect causing insulin resis- 
tance, i.e. the insulin receptor, phosphatases related to insulin 
action, glycogen synthase and the glucose transporters (36). 
Glucagon, probably acting through cAMP, may impair insu- 
lin signaling in the three early steps in insulin action after 
binding. There is a decrease in the insulin-stimulated recep- 
tor and ER.S-1 phosphorylation levels which is paralleled by a 
reduced association between IRS-1 and PI3-kinase in vivo in 
liver and muscle of glucagon-treated rats (37). 
Impaired insulin-stimulated glucose uptake in skeletal muscle 
from severely obese subjects is accompanied by a deficiency in 
insulin receptor signaling, which may contribute to decreased 
insulin action. Insulin-stimulated 2-deoxyglucose uptake is 
lower in muscle strips from obese subjects. Insulin stimula- 
tion of IRS-1 immunoprecipitable PI3-kinase activity also is 
markedly lower in obese subjects compared with controls. The 
obese individuals have a lower abundance of insulin recep- 
tors, IRS-1, and p85 subunit of PI3-kinase. In their skeletal 
muscle, insulin is less effective in stimulating tyrosine phos- 
phorylation (38). Hyperglycemia stimulates glucose transport 
by Ca
2+
-dependent activation that does not involve PI3-kinase 
activity and is separated from the mass-action effect of glu- 
cose on glucose transport (39). 
Incubation of Rat 1 fibroblasts expressing human insulin re- 
ceptors for 4 days in 27 mM D-glucose leads to impaired insu- 
lin stimulation of both oc-aminoisobutyric acid uptake and 
phosphorylation of pp!85 and receptor p-subunits in vivo. In 





 of insulin receptors from cells exposed 
to high glucose media are also impaired, although the bind- 
ing of insulin to high glucose media cells is unchanged (40). 
In hyperthyroidism, increased insulin-stimulated glucose trans- 
port is associated with an increase of GLUT4 which may be 
responsible for the increment of peripheral glucose utilization 
in hyperthyroidism. The effect of hypothyroidism on insulin 
action in adipocytes is characterized by a state of increased 
insulin sensitivity as indicated by the increase in insulin re- 
ceptor affinity and tyrosine kinase activity. Despite the marked 
reduction of GLUT4, insulin-stimulated glucose transport is 
not diminished, suggesting that functional activity of plasma 
membrane glucose transporters is enhanced in hypothyroidism 
(41). The regulation of the insulin receptor, IRS-1, and PI3- 
kinase contributes significantly to the insulin resistance in- 
duced by chronic hyperinsulinemia, but the glucocorticoid- 
induced insulin resistance is located beyond these early steps 
in insulin action (42). 
Upon chronic treatment of fibroblasts with insulin, conditions 
that mimic the hyperinsulinemia associated with insulin re- 
sistance, the membrane-associated insulin receptor P-subunit 
is proteolytically cleaved, resulting in the generation of a cy- 
tosolic fragment of the P-subunit (beta'), and that is inhibited 
by the thiol protease inhibitor E64. In 3T3-L1 adipocytes, (/) 
cytosolic beta' is generated by chronic insulin administration 
to the cells, and E64 inhibits the production of beta', (ii) chronic 
administration of insulin to the adipocytes leads to an insulin- 
resistant state, as measured by lipogenesis and glycogen syn- 
thesis, and E64 totally prevents the generation of this insulin- 
induced insulin resistance, (Hi) E64 has no effect on the insu- 
lin-induced downregulation of IRS-1, and therefore insulin 
resistance is not mediated by the down-regulation of insulin 
receptor substrate-1, (iv) under in vitro conditions, partially 
purified beta' stoichiometrically inhibits the insulin-induced 
autophosphorylation of the insulin receptor P-subunit, and (v) 
administration of E64 to obese Zucker fatty rats improves the 
insulin resistance of the rats compared with saline-treated ani- 
mals. These data indicate that beta' is a mediator of insulin 
resistance, and the mechanism of its action is inhibition of 
insulin-induced autophosphorylation of p-subunit of the insu- 
lin receptor (43). 
The insulin resistance in muscle maybe due to triacylglycerol 
accretion in the tissue itself. Diacylglycerol mimicks insulin 
action by increasing 2-deoxyglucose uptake and this is also 
reduced by triacylglycerol preloading, suggesting that the ef- 
fect is not mediated at the insulin receptor. Thus triacylglycerol 
may exert a direct effect on muscle cell insulin sensitivity pos- 




Insulin binding activates the receptor tyrosine kinase toward 
the ER.S-1. Phosphorylated ER.S-1 then interacts with p85 a- 
subunit of PI,-kinase, Nek, GRB-2, and Syp, thus branching 
insulin signals both for mitogenic and metabolic responses. 
The levels of these proteins are compared in adipose and liver 
tissues of nondiabetic mice and obese insulin-resistant dia- 
betic KKAy mice. IR and PI3-kinase p85 a protein levels are 
significantly lower in KKAy mice than in control nondiabetic 
mice, whereas IRS-1 protein levels are not altered. In con- 
trast, the protein levels of GRB-2, Nek, Syp, and GLUT1 are 
dramatically elevated in KKAy fat, with less striking changes 
in liver. Treatment of diabetic animals with pioglitazone, an 
insulin-sensitizing antihyperglycemic agent, partially corrects 
the expression of some of these proteins. Taken together these   
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findings suggest that the insulin-resistant diabetic condition 
is characterized by changes in expression of insulin signal 
transduction components that may be associated with altered 
glucose metabolism (45). :< / 'V.GO  
In effect, the recent data about the molecular mechanisms of 
insulin action may provide new insights into the pathophysi- 
ology and therapy of diabetes mellitus and other insulin resis- 
tant states. 
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